PharmaCyte Biotech, Inc. (PMCB): Operating Income
-$6.85M
Year ended 2026-04-30
-$7.01M
Trailing 12 months to 2026-07-31
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2026-04-30 | -$6.85M | n/m | 2026-07-29, From 2025-05-01 |
| 2025-04-30 | -$4.38M | n/m | 2026-07-29, From 2024-05-01 |
| 2024-04-30 | -$8.52M | n/m | 2025-08-11, From 2023-05-01 |
| 2023-04-30 | -$6.46M | n/m | 2024-08-13, From 2022-05-01 |
| 2022-04-30 | -$4.39M | n/m | 2023-07-31, From 2021-05-01 |
| 2021-04-30 | -$3.62M | n/m | 2022-07-28, From 2020-05-01 |
| 2020-04-30 | -$3.83M | n/m | 2021-08-10, From 2019-05-01 |
| 2019-04-30 | -$4.10M | n/m | 2020-08-13, From 2018-05-01 |
| 2018-04-30 | -$6.98M | n/m | 2019-08-13, From 2017-05-01 |
| 2017-04-30 | -$4.44M | n/m | 2018-07-20, From 2016-05-01 |
| 2016-04-30 | -$6.07M | n/m | 2017-07-27, From 2015-05-01 |
| 2015-04-30 | -$13.26M | n/m | 2016-07-29, From 2014-05-01 |
| 2014-04-30 | -$18.98M | n/m | 2016-07-29, From 2013-05-01 |
| 2013-04-30 | -$1.68M | n/m | 2016-01-19, From 2012-05-01 |
| 2012-04-30 | -$1.95M | n/a | 2013-07-29, From 2011-05-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| PharmaCyte Biotech, Inc. (PMCB) | 2026-04-30 | -$6.85M | n/m |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $18.07M | n/m |
| Amgen Inc (AMGN) | 2025-12-31 | $9.08B | +25.1% |
| Repligen Corp (RGEN) | 2025-12-31 | $55.17M | n/m |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | -$1.14M | n/m |
| Bio-Techne Corp (TECH) | 2026-06-30 | $251.89M | +146.3% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | -$36.62M | n/m |
| Gilead Sciences, Inc. (GILD) | 2025-12-31 | $10.02B | +503.0% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $340.99M | n/m |
Compare PMCB, VXRT, AMGN, RGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗